Cardiotoxicity

Project objectives

Prospective, low-risk, multicenter Phase IIB study with competitive enrollment to evaluate the efficacy and tolerability of ranolazine or standard therapies in the treatment of symptoms and/or instrumental findings of early cardiotoxicity induced by standard chemotherapy for the treatment of non-Hodgkin's lymphoma or adjuvant therapy of breast or colorectal cancer.

Start and end date

2011 - 2014

Project Manager

Giorgio Minotti - Local and National Coordinator

Coordinating institution of the project

Università Campus Bio-Medico di Roma - UR Pharmaceutical Sciences

Other Institutions involved

• IFO “Regina Elena”, Rome
• National Cancer Institute, Genoa
• National Cancer Institute, Naples
• Oncology Center Giovanni XXIII, Bari
• Gavazzeni Foundation, Bergamo
• Tor Vergata University, Rome
• Sapienza University, Rome
• University of Trieste
• Grassi Hospital, Ostia (Rome)
• San Pietro Hospital, Rome

Funding source(s).

Sponsored study